Загрузка видео...

Не удалось загрузить видео

На главную

#HDR #investment Few months post CABG patient presented with severe crippling angina. SVG to RCA gone. Cath outside. Discussed in office & hospital with patient & family (Drs) #HDR times 3 followed by PTCA achieved a small lumen. Would you stent or relook in few weeks? Salman Arain Lorenzo...

jedicath's profile picture

jedicath աǟզǟʀ.ǟɦʍɛɖ

10,137 subscribers

12,200 просмотров • 9 месяцев назад •via X (Twitter)

#HDR#investment#HDR
LIVE

Anya Rossi• Live Now

Private livecam show

Комментарии: 0

Нет доступных комментариев

Здесь появятся комментарии из оригинального поста

Похожие видео

#HDR #CTO101 is game Changer, 3v CTO PCI done in single session, hope to present full case at #TCT2025 at SFO. Patient in 70s NYHA 4, volume optimized, EF <30%, IABP supposed 3v CTO PCI done. 300 cc contrast, 2.5G, <3 hours. Salman Arain Evandro Martins F. MD Sripal Bangalore CanCTO EuroCTOClub Sanjog Kalra Mauro Carlino Darshan Doshi, MD, MS Kambis Mashayekhi Stéphane Rinfret, MD SM Mihajlo Kovacic 🫀📕/🔋🕹️ Pierfrancesco Agostoni Dr. Bill Lombardi Neisser M Gregor Leibundgut Allison Hall Elliot Smith Luiz Fernando Ybarra Rustem Dautov Abdul Mozid Mohammad Almutawa Basem Elbarouni jcspratt Tom Kaier Anja Øksnes Raja Hatem Lorenzo Azzalini jedicath աǟզǟʀ.ǟɦʍɛɖ Tsutomu Fujita MD Farouc Jaffer MD PhD Mohaned Egred Stefan Harb Edney Boston-Griffiths Amir Ravandi Dr Imran Hanif Hashmi Omer Goktekin MD Maksymilian Opolski Kalpa De Silva Faurie Benjamin Michael Megaly Jonathan Hill sharmainethiru Dr. Akshay Bagai Ignacio J. Amat Alex Truesdell Ziad Ali Ricardo Santiago Jack Hall Margaret McEntegart
0:44

#HDR #CTO101 is game Changer, 3v CTO PCI done in single session, hope to present full case at #TCT2025 at SFO. Patient in 70s NYHA 4, volume optimized, EF <30%, IABP supposed 3v CTO PCI done. 300 cc contrast, 2.5G, <3 hours. Salman Arain Evandro Martins F. MD Sripal Bangalore CanCTO EuroCTOClub Sanjog Kalra Mauro Carlino Darshan Doshi, MD, MS Kambis Mashayekhi Stéphane Rinfret, MD SM Mihajlo Kovacic 🫀📕/🔋🕹️ Pierfrancesco Agostoni Dr. Bill Lombardi Neisser M Gregor Leibundgut Allison Hall Elliot Smith Luiz Fernando Ybarra Rustem Dautov Abdul Mozid Mohammad Almutawa Basem Elbarouni jcspratt Tom Kaier Anja Øksnes Raja Hatem Lorenzo Azzalini jedicath աǟզǟʀ.ǟɦʍɛɖ Tsutomu Fujita MD Farouc Jaffer MD PhD Mohaned Egred Stefan Harb Edney Boston-Griffiths Amir Ravandi Dr Imran Hanif Hashmi Omer Goktekin MD Maksymilian Opolski Kalpa De Silva Faurie Benjamin Michael Megaly Jonathan Hill sharmainethiru Dr. Akshay Bagai Ignacio J. Amat Alex Truesdell Ziad Ali Ricardo Santiago Jack Hall Margaret McEntegart

Shariq Shamim

21,905 просмотров • 1 год назад

i often describe lightcell energy 🔆 as building portable dyson spheres. harnessing the power of spectrally pure, chemically fueled, man made stars. and it's remarkable that within just a few months of starting experiments, we started achieving brightnesses greater than the sun ever shines on earth. (note, in large part because it is 1/600,000th of our sky -- a limitation that our lightcells, our "dyson spheres" do not have, wrapping around our emitter.) within a few months, in a garden shed in Canada, we achieved over 3 suns, over 300,000 nits (cd/m^2). within a few more months, in our lab in San Francisco, Jon, Steve and I achieved almost 7 suns, 670,000 nits. albeit destructively to the apparatus! at temperatures that eroded our cutting torch, our salt supply, our quartz tubes, or cracked. our sapphire. but this was in 2023! to a large extent, the development over the past couple of years, from mid 2023, to 2024, and all this year, was a steady effort to invent and develop, in some cases for the first time, for any team on earth, a materials stack, and everything relevant to to, to make high temperature parts for (a) continuous operation, and (b) that could tolerate the extreme temperatures and chemical environment necessary to vaporize and condense salt, in a continuous cycle, with no moving parts. we basically continuously tried the stupidest thing that could possibly work. some things, like "use table salt" worked out amazingly well -- though they had knock on requirements, like now you have to reform and condense sodium chloride in heat exchangers other things, we tried all the stupidest things we could think of, until we ran out of stupid things to try. Then we had to start trying clever things. Like, the material that we chose, alumina, which can handle the molten NaCl, and the temperature, and will not further oxidize, since it is already an oxide, is super hard, as in high stiffness. It has finite thermal expansion. You must therefore relieve the thermal expansion via curvature. You can ONLY POSSIBLY survive thermal gradients and cycles through curvature. This will requires you pioneering a field. Roll up your sleeves. It has been an epic journey getting this far! Of course, it is yet unwritten if lightcell energy 🔆 can even complete it, much less by the end of the year, but, i can certainly set a medium term goal: more than 1,000,000 nits (cd/m^2, or ~1kw/m^2). brighter than any firework. maybe achieved by New Years? that will be a hell of a firework, and a beautiful omen. 1000x brighter than HDR, 10x brighter than 1kW/m^2, 10 suns, the max brightness of a Sun, incident on the Earth's surface here's the twist: it would now not be cheating to use recuperation AND oxygen enrichment if you're burning green hydrogen from electrolysis, since you can set up to hold on the oxygen. it's for this reason, and many more that I'm excited to welcome my heroes, Terraform Industries / Casey Handmer to lightcell energy 🔆's SAFE and Cap Table. We're building the Yin to Terraform Industries' Yang of abundant hydrogen and synthetic fuels. We are excited to work on both the technology and the multi megascale to gigascale development sites -- energy campuses, power centers -- to build revolutionary, cost effective proving grounds for synthetic fuels and energy technology. Thank you so much. We are empowered and inspired by your belief and investment in us. We will make it count 🫡 Thank you again, as well, very much, to our many investors who we have not yet tagged, and will tag, on our THANK YOU FOR SUPPORTING US ON SAFES WHILE WE WERE JUST A DREAM post, soon to come. Hope to paint funding announcements in a new, golden light!
0:43

i often describe lightcell energy 🔆 as building portable dyson spheres. harnessing the power of spectrally pure, chemically fueled, man made stars. and it's remarkable that within just a few months of starting experiments, we started achieving brightnesses greater than the sun ever shines on earth. (note, in large part because it is 1/600,000th of our sky -- a limitation that our lightcells, our "dyson spheres" do not have, wrapping around our emitter.) within a few months, in a garden shed in Canada, we achieved over 3 suns, over 300,000 nits (cd/m^2). within a few more months, in our lab in San Francisco, Jon, Steve and I achieved almost 7 suns, 670,000 nits. albeit destructively to the apparatus! at temperatures that eroded our cutting torch, our salt supply, our quartz tubes, or cracked. our sapphire. but this was in 2023! to a large extent, the development over the past couple of years, from mid 2023, to 2024, and all this year, was a steady effort to invent and develop, in some cases for the first time, for any team on earth, a materials stack, and everything relevant to to, to make high temperature parts for (a) continuous operation, and (b) that could tolerate the extreme temperatures and chemical environment necessary to vaporize and condense salt, in a continuous cycle, with no moving parts. we basically continuously tried the stupidest thing that could possibly work. some things, like "use table salt" worked out amazingly well -- though they had knock on requirements, like now you have to reform and condense sodium chloride in heat exchangers other things, we tried all the stupidest things we could think of, until we ran out of stupid things to try. Then we had to start trying clever things. Like, the material that we chose, alumina, which can handle the molten NaCl, and the temperature, and will not further oxidize, since it is already an oxide, is super hard, as in high stiffness. It has finite thermal expansion. You must therefore relieve the thermal expansion via curvature. You can ONLY POSSIBLY survive thermal gradients and cycles through curvature. This will requires you pioneering a field. Roll up your sleeves. It has been an epic journey getting this far! Of course, it is yet unwritten if lightcell energy 🔆 can even complete it, much less by the end of the year, but, i can certainly set a medium term goal: more than 1,000,000 nits (cd/m^2, or ~1kw/m^2). brighter than any firework. maybe achieved by New Years? that will be a hell of a firework, and a beautiful omen. 1000x brighter than HDR, 10x brighter than 1kW/m^2, 10 suns, the max brightness of a Sun, incident on the Earth's surface here's the twist: it would now not be cheating to use recuperation AND oxygen enrichment if you're burning green hydrogen from electrolysis, since you can set up to hold on the oxygen. it's for this reason, and many more that I'm excited to welcome my heroes, Terraform Industries / Casey Handmer to lightcell energy 🔆's SAFE and Cap Table. We're building the Yin to Terraform Industries' Yang of abundant hydrogen and synthetic fuels. We are excited to work on both the technology and the multi megascale to gigascale development sites -- energy campuses, power centers -- to build revolutionary, cost effective proving grounds for synthetic fuels and energy technology. Thank you so much. We are empowered and inspired by your belief and investment in us. We will make it count 🫡 Thank you again, as well, very much, to our many investors who we have not yet tagged, and will tag, on our THANK YOU FOR SUPPORTING US ON SAFES WHILE WE WERE JUST A DREAM post, soon to come. Hope to paint funding announcements in a new, golden light!

Danielle Fong 🔆

279,353 просмотров • 10 месяцев назад

Have you ever noticed that the lifestyle advice we give to IBD patients is often the same as general health advice? It's a simplifying realisation. Here are my six core pillars for a healthy lifestyle, whether you have IBD or not: ________ 1. Sleep Well Aim for 7-8 hours of actual sleep per night, not just time in bed. I use a Whoop to track mine, and I've learned I need an extra hour in bed to hit my sleep target. Measure your sleep - you might be surprised. ________ 2. Eat Right This sounds simple, but it's challenging in our current food environment. Any urban dwelling human spends most of his days dodging armies of delivery bikers bringing tepid fast food to people’s sofas. A whole ecosystem has come into existence to solve a problem we did not have. Here's what to aim for: • Cook from fresh ingredients when possible • Eat mostly plants +/- some good quality meats • Avoid processed foods where possible • Cook with healthy oils • Limit sugary foods • Try to eat communally - it's how we've evolved to eat. This is the cornerstone of the Mediterranean diet. If you have IBD, particularly small bowel Crohn’s disease, then much of this advice is turned on it’s head, as we look to limit fibre intake. I would say consult with your dietitian but we both know full well that this is a luxury that few people have, especially in the UK. ________ 3. Manage Stress Stress is unavoidable, so develop a system to handle it. This could be: • Talking to a friend • Journaling • Exercising • Meditating or practicing breathwork Find what works for you to sit with your emotions and deal with stress effectively. I have found a combination of exercise, journaling, and regular therapy works best for me. But like everyone, very much just a work in progress. In an ideal world I would recommend that IBD patients speak to a psychologist but this is something very few are able to access. One day maybe … until then hopefully these small pieces of advice are helpful. ________ 4. Exercise Regularly In my opinion, there's no better medicine than exercise. Aim for a mix of: • Cardio • Strength training • Stability/mobility work (especially important as we age) If you are new to exercise start slow and find something that you a) enjoy and b) can commit to on a regular basis. It might start with a 30 minute brisk walk each lunchtime. Those with dogs have a definite head-start here! There is some emerging evidence that exercising regularly may help patient with IBD stay in prolonged remission and avoid flares! ________ 5. Get Outside Spend time outdoors, preferably in nature. There's something uniquely beneficial about being in open spaces, living as we're meant to. ________ 6. Nurture Relationships Foster close friendships and family ties over time. Human existence is meant to be shared. In our increasingly tech-driven, solitary lives, it's crucial to remember the importance of human connection. These pillars can help you stay well physically, mentally, and spiritually, whether you're already healthy or living with a chronic illness like IBD. Many of these practices, particularly diet, stress management, and exercise, are great for your gut microbiome - which is especially crucial for those with IBD. ________ Remember, there's no one-size-fits-all approach. My hope is that you might find something in here helpful, wherever you are in your journey through life with, or without, IBD.
4:07

Have you ever noticed that the lifestyle advice we give to IBD patients is often the same as general health advice? It's a simplifying realisation. Here are my six core pillars for a healthy lifestyle, whether you have IBD or not: ________ 1. Sleep Well Aim for 7-8 hours of actual sleep per night, not just time in bed. I use a Whoop to track mine, and I've learned I need an extra hour in bed to hit my sleep target. Measure your sleep - you might be surprised. ________ 2. Eat Right This sounds simple, but it's challenging in our current food environment. Any urban dwelling human spends most of his days dodging armies of delivery bikers bringing tepid fast food to people’s sofas. A whole ecosystem has come into existence to solve a problem we did not have. Here's what to aim for: • Cook from fresh ingredients when possible • Eat mostly plants +/- some good quality meats • Avoid processed foods where possible • Cook with healthy oils • Limit sugary foods • Try to eat communally - it's how we've evolved to eat. This is the cornerstone of the Mediterranean diet. If you have IBD, particularly small bowel Crohn’s disease, then much of this advice is turned on it’s head, as we look to limit fibre intake. I would say consult with your dietitian but we both know full well that this is a luxury that few people have, especially in the UK. ________ 3. Manage Stress Stress is unavoidable, so develop a system to handle it. This could be: • Talking to a friend • Journaling • Exercising • Meditating or practicing breathwork Find what works for you to sit with your emotions and deal with stress effectively. I have found a combination of exercise, journaling, and regular therapy works best for me. But like everyone, very much just a work in progress. In an ideal world I would recommend that IBD patients speak to a psychologist but this is something very few are able to access. One day maybe … until then hopefully these small pieces of advice are helpful. ________ 4. Exercise Regularly In my opinion, there's no better medicine than exercise. Aim for a mix of: • Cardio • Strength training • Stability/mobility work (especially important as we age) If you are new to exercise start slow and find something that you a) enjoy and b) can commit to on a regular basis. It might start with a 30 minute brisk walk each lunchtime. Those with dogs have a definite head-start here! There is some emerging evidence that exercising regularly may help patient with IBD stay in prolonged remission and avoid flares! ________ 5. Get Outside Spend time outdoors, preferably in nature. There's something uniquely beneficial about being in open spaces, living as we're meant to. ________ 6. Nurture Relationships Foster close friendships and family ties over time. Human existence is meant to be shared. In our increasingly tech-driven, solitary lives, it's crucial to remember the importance of human connection. These pillars can help you stay well physically, mentally, and spiritually, whether you're already healthy or living with a chronic illness like IBD. Many of these practices, particularly diet, stress management, and exercise, are great for your gut microbiome - which is especially crucial for those with IBD. ________ Remember, there's no one-size-fits-all approach. My hope is that you might find something in here helpful, wherever you are in your journey through life with, or without, IBD.

Charlie Lees

12,537 просмотров • 2 лет назад

Expose Taliban Lies! Drugs Rehabilitation Center in Kabul was not hit by air strike, but destroyed by fire caused by burning explosives in nearby drone workshop. Pakistani jets took out a drone manufacturing facility in Kabul, causing explosives stored in the workshop to catch fire. Kicked up explosive sparks triggered fire in Drugs Rehab Center located 200 M from the depot. 📌Taliban made good use of this opportunity to play victim and claim 400 casualties. A closer look at the incident debunks Taliban claims. 📍Video clips taken by locals when strikes were ongoing, show a huge sparkling fire plume over the struck target. This is very much emblematic of explosives or highly inflammable fuel burning after being struck by bombs. 📍On night 16/ 17 Mar, immediately after Pakistani strikes, few journalists were reporting standing outside Rehab Center, which could be seen engulfed in flames. Pattern of fire in those videos is inconsistent with a bomb strike and more familiar to a large outbreak of fire. 📍Video clips aired by journalists taken to facility on 17 Mar show that all walls of barracks of the Rehab Center are intact. There are no blood stains, no body parts and no collapsed structures. This is not how a bomb destroys a building which causes 400 casualties. 📍Main sign board on Rehab Center was intact and undisturbed after the strikes. Bomb strike should have uprooted it in very first instance. 📍An injured patient evacuated from Rehab Center gave a statement in hospital soon after the incident, where he said that explosion occurred 200 M from Rehab Center. It perfectly matches layout of the target area, where struck workshop is located at same distance from the Rehab Center. 📍How can 400 male adults be killed from fire breaking out in single storey barracks, with windows and multiple exits available in each barrack. In-fact barracks were occupied only by few dozen people, not 2000 as Taliban would like the world to believe. All were able to escape, except few who were directly hit by burning explosives falling from the sky. 📍Taliban were using same compound for storing explosives, ammunition, manufacturing armed drones and running a Drugs Rehab Center. 📍Taliban Regime either lacked capacity to put out the fire or intentionally allowed the fire to rage to accrue propaganda benefits. Similar, preposterous claims were made during Lal Masjid operation in Islamabad in 2007, where terrorists spread propaganda that 1500 girls students had been killed. Due to slow response by the state, it was only after many months when facts were revealed that not a single girl had been killed during the operation. Pakistan struck total six targets during air raid. Interestingly, Taliban have not said a word about other five sites. #ExposeTalibanLies
0:53

Expose Taliban Lies! Drugs Rehabilitation Center in Kabul was not hit by air strike, but destroyed by fire caused by burning explosives in nearby drone workshop. Pakistani jets took out a drone manufacturing facility in Kabul, causing explosives stored in the workshop to catch fire. Kicked up explosive sparks triggered fire in Drugs Rehab Center located 200 M from the depot. 📌Taliban made good use of this opportunity to play victim and claim 400 casualties. A closer look at the incident debunks Taliban claims. 📍Video clips taken by locals when strikes were ongoing, show a huge sparkling fire plume over the struck target. This is very much emblematic of explosives or highly inflammable fuel burning after being struck by bombs. 📍On night 16/ 17 Mar, immediately after Pakistani strikes, few journalists were reporting standing outside Rehab Center, which could be seen engulfed in flames. Pattern of fire in those videos is inconsistent with a bomb strike and more familiar to a large outbreak of fire. 📍Video clips aired by journalists taken to facility on 17 Mar show that all walls of barracks of the Rehab Center are intact. There are no blood stains, no body parts and no collapsed structures. This is not how a bomb destroys a building which causes 400 casualties. 📍Main sign board on Rehab Center was intact and undisturbed after the strikes. Bomb strike should have uprooted it in very first instance. 📍An injured patient evacuated from Rehab Center gave a statement in hospital soon after the incident, where he said that explosion occurred 200 M from Rehab Center. It perfectly matches layout of the target area, where struck workshop is located at same distance from the Rehab Center. 📍How can 400 male adults be killed from fire breaking out in single storey barracks, with windows and multiple exits available in each barrack. In-fact barracks were occupied only by few dozen people, not 2000 as Taliban would like the world to believe. All were able to escape, except few who were directly hit by burning explosives falling from the sky. 📍Taliban were using same compound for storing explosives, ammunition, manufacturing armed drones and running a Drugs Rehab Center. 📍Taliban Regime either lacked capacity to put out the fire or intentionally allowed the fire to rage to accrue propaganda benefits. Similar, preposterous claims were made during Lal Masjid operation in Islamabad in 2007, where terrorists spread propaganda that 1500 girls students had been killed. Due to slow response by the state, it was only after many months when facts were revealed that not a single girl had been killed during the operation. Pakistan struck total six targets during air raid. Interestingly, Taliban have not said a word about other five sites. #ExposeTalibanLies

Maximus47

12,873 просмотров • 6 месяцев назад

Update: Young Cody Hudson (26- FL) will have the first of two skin graft surgeries to his extensively micro clot injured leg tomorrow. He is still hospitalized in critical condition for day 25 now, fighting for his life in advanced heart failure and at risk of leg amputation caused by blood clotting and micro-clotting as a result of his severe, vaccine-induced autoimmune clotting disorder that is well documented, peer reviewed and published and that he was left with since 2021. He was recently medivac transferred by helicopter to his current hospital in order to access a specialized, multidisciplinary care team equipped to handle his rare combination of heart failure, strokes, micro-clotting, and critical need for immune modulation to stop this aggressive autoimmune process. In June, he had a massive, inflammatory autoimmune event in which micro-clots in his blood have completely cut off circulation, acting like a severe third-degree burn all the way around his lower leg from the knee down. We had to request immediate helicopter transfer to his current hospital system on Father’s Day just a few weeks ago, to avoid leg amputation and to save his leg. I have been providing extensive wound care in the hospital for the past three weeks taking care of Cody’s leg- on my own and keeping it free of infection with the support of the staff here at the hospital. Tomorrow, he will have surgery to remove the dead tissue— this is the first of two skin graft surgeries on his left leg (or for both legs if they determine his right leg is severe enough)- A sobering aspect of these surgeries is that any surgery for a patient with Cody’s blood clotting condition is a terrifying tightrope between fatal blood clots and catastrophic bleeding with an extreme high risk compared to the general population. If the dead tissue is not removed- he could easily die of infection- we have been able to keep him free of infection in the legs, but the risk of death by infection is grater this surgery outweighs the risk of infection killing him. Because his case is so rare, I have dedicated years to researching these specific autoimmune injuries. My research is utilized globally in litigation and active state and federal government investigations. Cody’s medical team treats me as one of the experts on his team. I perform his specialized leg care daily and actively provide research in his case. He needs his mom and dad have to be at his bedside to help him. But we are at a breaking point. My husband is our sole provider, and he has missed three months to of work with zero pay to help me safely lift 6'3" Cody. This is the 5th year of Cody’s terminal illness and the extensive medical need have caused crushing financial hardship on our family. We desperately need to stay at Cody's side in the hospital to help save his life and protect him. We cannot do this alone anymore—we need your help. Please watch the short video below, this is the first time Cody has spoken publicly in some time. Please pray for Cody and the vaccine injured, donate to HELP Cody if you can, and REPOST to SHARE our fight to bring his important story to the public. Share on your FB and Instagram please and provide his GSG link. 🙏🌍👇 Give send go link:
0:26

Update: Young Cody Hudson (26- FL) will have the first of two skin graft surgeries to his extensively micro clot injured leg tomorrow. He is still hospitalized in critical condition for day 25 now, fighting for his life in advanced heart failure and at risk of leg amputation caused by blood clotting and micro-clotting as a result of his severe, vaccine-induced autoimmune clotting disorder that is well documented, peer reviewed and published and that he was left with since 2021. He was recently medivac transferred by helicopter to his current hospital in order to access a specialized, multidisciplinary care team equipped to handle his rare combination of heart failure, strokes, micro-clotting, and critical need for immune modulation to stop this aggressive autoimmune process. In June, he had a massive, inflammatory autoimmune event in which micro-clots in his blood have completely cut off circulation, acting like a severe third-degree burn all the way around his lower leg from the knee down. We had to request immediate helicopter transfer to his current hospital system on Father’s Day just a few weeks ago, to avoid leg amputation and to save his leg. I have been providing extensive wound care in the hospital for the past three weeks taking care of Cody’s leg- on my own and keeping it free of infection with the support of the staff here at the hospital. Tomorrow, he will have surgery to remove the dead tissue— this is the first of two skin graft surgeries on his left leg (or for both legs if they determine his right leg is severe enough)- A sobering aspect of these surgeries is that any surgery for a patient with Cody’s blood clotting condition is a terrifying tightrope between fatal blood clots and catastrophic bleeding with an extreme high risk compared to the general population. If the dead tissue is not removed- he could easily die of infection- we have been able to keep him free of infection in the legs, but the risk of death by infection is grater this surgery outweighs the risk of infection killing him. Because his case is so rare, I have dedicated years to researching these specific autoimmune injuries. My research is utilized globally in litigation and active state and federal government investigations. Cody’s medical team treats me as one of the experts on his team. I perform his specialized leg care daily and actively provide research in his case. He needs his mom and dad have to be at his bedside to help him. But we are at a breaking point. My husband is our sole provider, and he has missed three months to of work with zero pay to help me safely lift 6'3" Cody. This is the 5th year of Cody’s terminal illness and the extensive medical need have caused crushing financial hardship on our family. We desperately need to stay at Cody's side in the hospital to help save his life and protect him. We cannot do this alone anymore—we need your help. Please watch the short video below, this is the first time Cody has spoken publicly in some time. Please pray for Cody and the vaccine injured, donate to HELP Cody if you can, and REPOST to SHARE our fight to bring his important story to the public. Share on your FB and Instagram please and provide his GSG link. 🙏🌍👇 Give send go link:

Heather Hudson

47,386 просмотров • 2 месяцев назад

HE WROTE "0800-F***-YOU" TO AN NHS WHISTLEBLOWER. THE TRUST GAVE HIM AN AWARD. A few weeks ago I posted Sharmila Chowdhury's sharmila chowdhury story. That posts reached nearly 800,000 views. Thank you. That number tells me people understand exactly how serious this is. So let me give you one more detail from this case. Because it deserves its own post. Quick recap for anyone new here. Sharmila gave 30 years of spotless service to the @NHS. She caught two consultant radiologists at Ealing Hospital billing the NHS while working privately down the road. She reported it. They sacked her on fabricated allegations and blacklisted her across the NHS. She won at tribunal. They ignored it. She developed cancer. They carried on. Now here's the detail. The man who made those fabricated allegations against her was Mike McWha, the PACS/RIS manager at Ealing Hospital NHS Trust. The same Mike McWha who had already failed to upload nuclear medicine reports for approximately 100 patients over six months. Patients with potentially life-threatening conditions. Sharmila had formally raised that against him in writing before he turned on her. He also sent an email signed off "0800-F***-YOU-B****." That same year, Ealing Hospital NHS Trust put Mike McWha in their Annual Report and gave him the "Top Mentor" award. Not a disciplinary hearing. Not a formal investigation. A published award. In the Annual Report. Sharmila was escorted out of the building in front of her staff. Her colleagues were warned they would face the same treatment if they contacted her. Her name was removed from her office door within two weeks. Her post was advertised while she was still suspended. Twelve staff members submitted written statements in her support. The Trust ignored all of them. She won. He got a plaque. Nearly 800,000 people looked at this case and said this matters. It does. Share this one too please. Full case: sharmilachowdhury com Sources: Health Select Committee written evidence | The Guardian | BBC News (UK) | Channel 4 | Daily Mail | The Independent | The Times and Sunday Times | The Mirror
3:05

HE WROTE "0800-F***-YOU" TO AN NHS WHISTLEBLOWER. THE TRUST GAVE HIM AN AWARD. A few weeks ago I posted Sharmila Chowdhury's sharmila chowdhury story. That posts reached nearly 800,000 views. Thank you. That number tells me people understand exactly how serious this is. So let me give you one more detail from this case. Because it deserves its own post. Quick recap for anyone new here. Sharmila gave 30 years of spotless service to the @NHS. She caught two consultant radiologists at Ealing Hospital billing the NHS while working privately down the road. She reported it. They sacked her on fabricated allegations and blacklisted her across the NHS. She won at tribunal. They ignored it. She developed cancer. They carried on. Now here's the detail. The man who made those fabricated allegations against her was Mike McWha, the PACS/RIS manager at Ealing Hospital NHS Trust. The same Mike McWha who had already failed to upload nuclear medicine reports for approximately 100 patients over six months. Patients with potentially life-threatening conditions. Sharmila had formally raised that against him in writing before he turned on her. He also sent an email signed off "0800-F***-YOU-B****." That same year, Ealing Hospital NHS Trust put Mike McWha in their Annual Report and gave him the "Top Mentor" award. Not a disciplinary hearing. Not a formal investigation. A published award. In the Annual Report. Sharmila was escorted out of the building in front of her staff. Her colleagues were warned they would face the same treatment if they contacted her. Her name was removed from her office door within two weeks. Her post was advertised while she was still suspended. Twelve staff members submitted written statements in her support. The Trust ignored all of them. She won. He got a plaque. Nearly 800,000 people looked at this case and said this matters. It does. Share this one too please. Full case: sharmilachowdhury com Sources: Health Select Committee written evidence | The Guardian | BBC News (UK) | Channel 4 | Daily Mail | The Independent | The Times and Sunday Times | The Mirror

Artur Nadolny

23,293 просмотров • 4 месяцев назад

🚨🚨10-Year Longitudinal Data On Ketogenic Diet Adverse Events, Bone Mineral Density, Thyroid Function, and Kidney Function: PART 2🚨🚨 NEW DATA OUT TODAY: We (Joseph C. Watso, PhD/ Austin Robinson/ Samuel Klein) just published our PART 2 paper looking at long-term safety and clinical efficacy of ketogenic diet on: ☠️Adverse Events 🦴Bone Mineral Density 🔥Thyroid Function 🫘Kidney Function ...in part 1 we measured advanced cardiovascular health profile in an adult with elevated cardiovascular risk (type 1 diabetes) who followed a ketogenic diet for 10 years and sustained euglycemia (10-Year HbA1c 5.5%). See paper here: PART 2: What did we find? 👉PLEASE WATCH 📷 VIDEO ABSTRACT here ( 180mg/dL). Patient also presented with intact hypoglycemic awareness. 🦴2) Bone Mineral Density: Prior data suggests that short term ketogenic diet may impair markers of bone modeling/remodeling. However, most of these report are short in nature. People with type 1 diabetes are at HIGH risk for lower bone mineral density and fracture (hyperglycemia is risk factor). Here, we observed no negative impact on bone mineral density (using GOLD STANDARD DXA) on a ketogenic diet, despite 10 years of aging with type 1 diabetes. 🔥3) Thyroid Function: Concerns have been raised on how reducing carbohydrates may shift thyroid hormone status and metabolism. However, most of these studies are </=7 days in length. Following a ketogenic diet over a 10-year period, here we observe no negative impact on thyroid function with a 10-year ketogenic diet. 🫘4) Kidney Function: Microvascular disease is a very common complication of type 1 diabetes as hyperglycemia damages the small blood vessel in the kidneys. Adverse structural kidney changes are observed in children with type 1 diabetes as early as 1.5-5 years post diagnosis with eGFR declining over time. We did not observe any deterioration of kidney function in patient with type 1 diabetes over a 10-year period while achieving 10-Year 5.5% HbA1c following a ketogenic diet. 🚨⚠️9) LIMITATIONS: Reminder on limitations. This is an individual case. The importance of this data is in the sheer absence of short or long-term data, hypothesized risk of a KD, and popularity and use of KD which we hope help generate future research questions. 🗒️CONCLUSIONS: In the longest known longitudinal report of a ketogenic diet in a patient with type 1 diabetes, we observed no severe adverse events or negative impacts on bone, kidney, or thyroid health. We in our PART 1 paper, we observed above average cardiovascular disease health. These initial findings should provoke further research into interventions like ketogenic diets to reduce the long-term health risks faced by those living with T1D while closely monitoring both traditional and advanced cardiovascular risk markers. Especially considering that currently available therapies do no reliably allow patients to achieve <7% HbA1c, let alone <5.7% HbA1c. Joseph C. Watso, PhD Cardiovascular & Applied Physiology Lab Studying how health behaviors (e.g., diet, exercise, etc.) affect cardiovascular health and physiology Sansum Diabetes Research Institute Studying how lifestyle, tools, and medicine affect people with diabetes. @fsucehhs FSU Research FSU ISSM AJP-Cell Physiology The diaTribe Foundation Beyond Type 1 Michael Riddell, PhD Nick Norwitz MD PhD Metabolic Mind Dominic D'Agostino Benjamin Bikman
2:53

🚨🚨10-Year Longitudinal Data On Ketogenic Diet Adverse Events, Bone Mineral Density, Thyroid Function, and Kidney Function: PART 2🚨🚨 NEW DATA OUT TODAY: We (Joseph C. Watso, PhD/ Austin Robinson/ Samuel Klein) just published our PART 2 paper looking at long-term safety and clinical efficacy of ketogenic diet on: ☠️Adverse Events 🦴Bone Mineral Density 🔥Thyroid Function 🫘Kidney Function ...in part 1 we measured advanced cardiovascular health profile in an adult with elevated cardiovascular risk (type 1 diabetes) who followed a ketogenic diet for 10 years and sustained euglycemia (10-Year HbA1c 5.5%). See paper here: PART 2: What did we find? 👉PLEASE WATCH 📷 VIDEO ABSTRACT here ( 180mg/dL). Patient also presented with intact hypoglycemic awareness. 🦴2) Bone Mineral Density: Prior data suggests that short term ketogenic diet may impair markers of bone modeling/remodeling. However, most of these report are short in nature. People with type 1 diabetes are at HIGH risk for lower bone mineral density and fracture (hyperglycemia is risk factor). Here, we observed no negative impact on bone mineral density (using GOLD STANDARD DXA) on a ketogenic diet, despite 10 years of aging with type 1 diabetes. 🔥3) Thyroid Function: Concerns have been raised on how reducing carbohydrates may shift thyroid hormone status and metabolism. However, most of these studies are </=7 days in length. Following a ketogenic diet over a 10-year period, here we observe no negative impact on thyroid function with a 10-year ketogenic diet. 🫘4) Kidney Function: Microvascular disease is a very common complication of type 1 diabetes as hyperglycemia damages the small blood vessel in the kidneys. Adverse structural kidney changes are observed in children with type 1 diabetes as early as 1.5-5 years post diagnosis with eGFR declining over time. We did not observe any deterioration of kidney function in patient with type 1 diabetes over a 10-year period while achieving 10-Year 5.5% HbA1c following a ketogenic diet. 🚨⚠️9) LIMITATIONS: Reminder on limitations. This is an individual case. The importance of this data is in the sheer absence of short or long-term data, hypothesized risk of a KD, and popularity and use of KD which we hope help generate future research questions. 🗒️CONCLUSIONS: In the longest known longitudinal report of a ketogenic diet in a patient with type 1 diabetes, we observed no severe adverse events or negative impacts on bone, kidney, or thyroid health. We in our PART 1 paper, we observed above average cardiovascular disease health. These initial findings should provoke further research into interventions like ketogenic diets to reduce the long-term health risks faced by those living with T1D while closely monitoring both traditional and advanced cardiovascular risk markers. Especially considering that currently available therapies do no reliably allow patients to achieve <7% HbA1c, let alone <5.7% HbA1c. Joseph C. Watso, PhD Cardiovascular & Applied Physiology Lab Studying how health behaviors (e.g., diet, exercise, etc.) affect cardiovascular health and physiology Sansum Diabetes Research Institute Studying how lifestyle, tools, and medicine affect people with diabetes. @fsucehhs FSU Research FSU ISSM AJP-Cell Physiology The diaTribe Foundation Beyond Type 1 Michael Riddell, PhD Nick Norwitz MD PhD Metabolic Mind Dominic D'Agostino Benjamin Bikman

Andrew Koutnik, Ph.D.

62,220 просмотров • 2 лет назад

There are some shocking revelations about the Nihal Vihar family dispute case in Outer Delhi 🚨🤯 What everyone already knows: - Vinay Gupta came home and asked his wife Rekha Gupta to apply medicine to one of their twin children as he got hurt few days ago. - Rekha got rattled, went outside and returned within 10 minutes with her brothers and sister-in-law. Before leaving, she switched off the CCTV cameras inside the house so there would be no visual evidence. - Vinay’s mother initially thought they had simply come for a visit. She asked Vinay’s father to offer them water and sweets and turn on the AC for them so they could relax. - While she was outside talking to neighbours, she returned and saw both of Rekha’s brothers pinning Vinay down on the bed and strangling him, with the younger brother placing his leg on Vinay’s stomach. - She tried to stop them and begged them to spare her son, but Rekha’s sister-in-law grabbed her by the hair and pushed her away. - They also beat Vinay’s father, leaving him severely injured. - Vinay’s mother rushed outside the moment she got a chance and called the neighbours for help. But by the time people arrived, Vinay had suffered severe injuries. - He was rushed to the hospital, but the moment they reached, doctors found that he had no pulse. Vinay was no more. His sister has now revealed some shocking things that happened before the incident 🚨 - She said Rekha used to fight with Vinay over small things, including household chores and taking care of their children. - She would repeatedly tell him: “I belong to a rich family. You have no status to tell me what to do.” - She threatened him multiple times, saying: “I’ll bring my brothers and get you beaten if you irritate me again.” - Her brothers had come to their house several times before, but the situation never escalated to this level. According to Vinay’s sister, they would threaten that “it is their family’s history to eliminate son-in-laws if they don’t follow their way.” - She further said that, as far as she knew, something similar had happened with the husband of Rekha’s elder sister. The neighbours added that when Rekha and her brothers were arrested, there was no sign of guilt or remorse. Instead, they were reportedly justifying Vinay’s killing. Vinay’s aunt, his mother’s sister, said: “Their whole family was evil. We mistakenly married our son to their daughter, and now we are suffering because of that decision.” She recalled seeing Vinay completely pale while they were taking him to the hospital. He was telling her that he couldn’t breathe, and she said it was heartbreaking that she couldn’t relieve him from that pain. She also recalled telling Vinay just a few days earlier: “If the marriage isn’t working, just divorce her.” But Vinay told her: “Maasi, I have two children. I have to think about them before myself. If I divorce her, those two will probably live most of their lives without their father. I don’t want that. I love them a lot.” ❤️‍🩹 He was thinking about his children even when his own marriage had fallen apart. He was so selfless that he chose to stay for his children and tragically, that very selflessness has costed him his life. 😔 Hope the judiciary delivers justice to Vinay and his family, and that everyone responsible for this horrific crime receives the strictest punishment under the law. 🙏
1:22

There are some shocking revelations about the Nihal Vihar family dispute case in Outer Delhi 🚨🤯 What everyone already knows: - Vinay Gupta came home and asked his wife Rekha Gupta to apply medicine to one of their twin children as he got hurt few days ago. - Rekha got rattled, went outside and returned within 10 minutes with her brothers and sister-in-law. Before leaving, she switched off the CCTV cameras inside the house so there would be no visual evidence. - Vinay’s mother initially thought they had simply come for a visit. She asked Vinay’s father to offer them water and sweets and turn on the AC for them so they could relax. - While she was outside talking to neighbours, she returned and saw both of Rekha’s brothers pinning Vinay down on the bed and strangling him, with the younger brother placing his leg on Vinay’s stomach. - She tried to stop them and begged them to spare her son, but Rekha’s sister-in-law grabbed her by the hair and pushed her away. - They also beat Vinay’s father, leaving him severely injured. - Vinay’s mother rushed outside the moment she got a chance and called the neighbours for help. But by the time people arrived, Vinay had suffered severe injuries. - He was rushed to the hospital, but the moment they reached, doctors found that he had no pulse. Vinay was no more. His sister has now revealed some shocking things that happened before the incident 🚨 - She said Rekha used to fight with Vinay over small things, including household chores and taking care of their children. - She would repeatedly tell him: “I belong to a rich family. You have no status to tell me what to do.” - She threatened him multiple times, saying: “I’ll bring my brothers and get you beaten if you irritate me again.” - Her brothers had come to their house several times before, but the situation never escalated to this level. According to Vinay’s sister, they would threaten that “it is their family’s history to eliminate son-in-laws if they don’t follow their way.” - She further said that, as far as she knew, something similar had happened with the husband of Rekha’s elder sister. The neighbours added that when Rekha and her brothers were arrested, there was no sign of guilt or remorse. Instead, they were reportedly justifying Vinay’s killing. Vinay’s aunt, his mother’s sister, said: “Their whole family was evil. We mistakenly married our son to their daughter, and now we are suffering because of that decision.” She recalled seeing Vinay completely pale while they were taking him to the hospital. He was telling her that he couldn’t breathe, and she said it was heartbreaking that she couldn’t relieve him from that pain. She also recalled telling Vinay just a few days earlier: “If the marriage isn’t working, just divorce her.” But Vinay told her: “Maasi, I have two children. I have to think about them before myself. If I divorce her, those two will probably live most of their lives without their father. I don’t want that. I love them a lot.” ❤️‍🩹 He was thinking about his children even when his own marriage had fallen apart. He was so selfless that he chose to stay for his children and tragically, that very selflessness has costed him his life. 😔 Hope the judiciary delivers justice to Vinay and his family, and that everyone responsible for this horrific crime receives the strictest punishment under the law. 🙏

SaffronVigilant

40,213 просмотров • 1 месяц назад

𝗧𝗵𝗲 $NWBO 𝗗𝗖𝗩𝗮𝘅-𝗟 𝘁𝗿𝗶𝗮𝗹 𝗶𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗱𝗼𝗻𝗲. 𝗧𝗵𝗲 𝗙𝗗𝗔 𝗵𝗮𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝘄𝗿𝗶𝘁𝘁𝗲𝗻 𝘁𝗵𝗲 𝗽𝗹𝗮𝘂𝘀𝗶𝗯𝗹𝗲 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝗽𝗮𝘁𝗵𝘄𝗮𝘆. 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗹𝗲𝗳𝘁 𝗶𝘀 𝘁𝗼 𝗮𝘀𝘀𝗲𝗺𝗯𝗹𝗲 𝗶𝘁 𝗮𝗻𝗱 𝗳𝗶𝗹𝗲. #DCVax-L is a vaccine made for each patient from their own dendritic cells, the immune cells that teach the rest of the immune system what to attack, loaded with their own tumor. It treats #glioblastoma, the deadliest brain cancer. An American company developed it, yet Americans have to go to Europe to get it. #DCVaxForBraelyn The FDA has spent the past year writing down how it wants to judge treatments like this one. The core evidence it asks for already exists. One question decides this: can the FDA evaluate DCVax-L for approval under the plausible mechanism framework, on the evidence already generated? Read against every document the agency has published on the framework, the answer is yes. 𝗧𝗵𝗲 𝗽𝗹𝗮𝗻 𝗶𝗻 𝘁𝗵𝗿𝗲𝗲 𝘀𝘁𝗲𝗽𝘀 1. File the biologics license application (BLA) and ask the FDA's biologics center (CBER) for review under the plausible mechanism framework. A BLA is not another trial. It is the dossier the FDA decides on, and the framework changes what counts as sufficient inside it. The framework itself needs no new statute and no special designation. A sponsor asks for it. 2. Ask for full approval on survival, with no new randomized trial. The completed phase 3 is the pivotal study. Mechanism, a related product, a related stage of the disease and independent natural history are the confirmatory evidence. A registry of every treated patient supplies the follow-up. 3. Open access alongside the filing. An expanded access treatment protocol does not have to wait for the BLA; it can begin 30 days after the FDA receives it. Filing the BLA satisfies Right to Try's application condition. 𝗪𝗵𝗮𝘁 𝘁𝗵𝗲 𝗙𝗗𝗔 𝗵𝗮𝘀 𝘄𝗿𝗶𝘁𝘁𝗲𝗻 𝗱𝗼𝘄𝗻 Nov 2025, NEJM, Prasad and Makary: the plausible mechanism framework. Five questions. Built for cell and gene therapies first, and available for common diseases, particularly those "for which there are no proven alternative treatments." Feb 2026, NEJM: one adequate and well-controlled study plus confirmatory evidence is the FDA's default basis for approval. Feb 2026 draft guidance: an externally controlled study against a well-characterized natural history can be the pivotal study. Confirmatory evidence includes mechanism, target engagement and "exposure-response on biomarkers and clinical outcomes." The product can target "a well-characterized downstream or compensatory mechanism with a clear mechanistic rationale." June 2026 draft guidance: six conditions under which an external control supports effectiveness. The plausible mechanism framework named as an example of FDA regulatory flexibility in critical settings. "Even small effects may be clinically meaningful when the effect is on survival or irreversible morbidity." Why it exists: to bring regulatory flexibility to individualized therapies where the conventional model does not fit. The guidance names gene and RNA therapies, then says "the general concepts may apply to other types of individualized therapies": therapies that target "a specific pathophysiologic abnormality serving as the root cause of a disease." The FDA's own announcement: the guidance "leaves open the potential that this framework may apply to additional tailored therapeutics provided they directly address the underlying specific cause of the disease." The framework is not a new approval standard. It is how the FDA reads evidence under the standard that already exists. That is exactly why it can be asked for today. 𝗪𝗵𝘆 𝗴𝗹𝗶𝗼𝗯𝗹𝗮𝘀𝘁𝗼𝗺𝗮 𝗶𝘀 𝘁𝗵𝗲 𝗰𝗮𝘀𝗲 𝗶𝘁 𝘄𝗮𝘀 𝘄𝗿𝗶𝘁𝘁𝗲𝗻 𝗳𝗼𝗿 No proven alternative: recurrent GBM has no established standard of care. Of 400+ trials since 2005, only one phase 3 in newly diagnosed and none in recurrent disease had shown a survival benefit. High and predictable mortality: the exact case FDA regulations name for historical controls, "certain malignancies." Life-threatening in the regulation's own terms: a disease "where the end point of clinical trial analysis is survival." Individualized: a different product for every patient, made from their own cells and their own tumor, aimed at the root cause, the broken instruction layer. Orphan designation in the US and Europe. 𝗧𝗵𝗲 𝗽𝗶𝘃𝗼𝘁𝗮𝗹 𝘀𝘁𝘂𝗱𝘆 𝗶𝘀 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 331 patients, 94 sites, randomized, double blind. 64 of 99 placebo patients crossed over at recurrence, so survival was measured against 2,006 contemporaneous matched control patients from 15 randomized trials. Newly diagnosed: 19.3 vs 16.5 months, HR 0.80, p=.002. Alive at 5 years: 13.0% vs 5.7%. Recurrent: 13.2 vs 7.8 months, HR 0.58, p<.001. That is a 42% lower risk of death. The benefit widened over time, and it was largest in the patients who fare worst. Why no second trial? The completed trial, the crossover and the survival evidence make the case, and the FDA's June guidance names the ethical stake: after "a substantial decrease in mortality," a second trial "would generally present significant ethical concerns." 𝗧𝗵𝗲 𝟮𝟬𝟮𝟲 𝗿𝗲𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 The phase 3 paper named its own limitation: without patient-level control data, "propensity score matching could not be performed." The critics named the missing methods: "propensity score matching or inverse probability weighting." In 2026 Northwest obtained individual patient data from three independent randomized trials and had independent statisticians run exactly those two methods. Propensity score matching pairs each DCVax-L patient with control patients who had the same prognostic profile, so like is compared with like. Presented at BNOS in July 2026; peer-reviewed publication is the next step. Propensity score matching: HR 0.69 to 0.77. Median survival +3.4 to +6.3 months. p .004 to .027. The original cohort-level analysis showed +2.8. When the matching got finer, the benefit got bigger. The survival advantage held under both patient-level methods and was larger than the original cohort-level estimate. Northwest reports sensitivity analyses for hidden confounding; the published paper should give the values. The method has been tested in this exact disease. In May 2026, the INSIGhT investigators replaced their own randomized control arm with propensity-matched external controls. For three drugs that had failed randomized testing, the method also found no benefit: HR 1.00, 0.93, 0.88. "Carefully matched external controls" produced "treatment effect estimates that were similar" to the randomized analyses. The method did not invent a benefit. Applied to DCVax-L, it found one. And the authorship closes the loop. In 2023, Dana-Farber statisticians Rahman, Ventz and Trippa wrote that they were "not aware of independent validations of these analytic methods in a GBM trial context." Rahman and Trippa are the senior authors of the 2026 INSIGhT validation. The critics asked for patient-level data and a validated method. By 2026 both existed. That supports the method the DCVax-L reanalysis used; publishing that analysis in full is step one. And it is the form a BLA requires: FDA guidance says applications "must include" patient-level data for the external control arm. 𝗧𝗵𝗲 𝗙𝗗𝗔'𝘀 𝘀𝗶𝘅 𝘁𝗲𝘀𝘁𝘀 𝗳𝗼𝗿 𝗮𝗻 𝗲𝘅𝘁𝗲𝗿𝗻𝗮𝗹 𝗰𝗼𝗻𝘁𝗿𝗼𝗹, 𝗮𝗻𝘀𝘄𝗲𝗿𝗲𝗱 1. Well-defined natural history: 2,006 controls from 15 randomized trials. 2. Very similar populations: 14 prespecified criteria, chosen by an independent firm, validated against all 15 source trials, now matched patient by patient. 3. Similar treatments: in newly diagnosed disease, surgery, radiation and temozolomide in both groups. 4. Objective endpoint: death. 5. Comparable start: survival from randomization after radiotherapy in both groups. Drop the two control trials that admitted early progressors: HR still 0.80. 6. An effect too large to be bias: five-year survival more than doubled, HR 0.58 at recurrence, and the effect grew when matching tightened. 𝗧𝗵𝗲 𝗽𝗹𝗮𝘂𝘀𝗶𝗯𝗹𝗲 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝗰𝗿𝗶𝘁𝗲𝗿𝗶𝗮, 𝘄𝗼𝗿𝗱 𝗳𝗼𝗿 𝘄𝗼𝗿𝗱 The FDA's five elements, quoted exactly from its February 2026 draft guidance ( lines 26 to 32), each answered: 1. "Identifying a specific genetic, cellular, or molecular abnormality with a clear connection between specific alteration and disease indication." (line 26) ✓ Met: in GBM, the dendritic cells that should teach T cells what to attack are overridden by suppressive immune cells. A tumor never presented for attack grows unopposed. 2. "Developing a therapy that targets the underlying or proximate pathogenic biological alterations." (line 28) ✓ Met: DCVax-L supplies the patient's own dendritic cells, loaded with their own tumor and prepared outside the suppressive tumor environment, to restore tumor-directed T-cell instruction. 3. "Relying on a well-characterized natural history of the disease in an untreated population." (line 30) ✓ Met: 2,006 controls from 15 randomized trials, patient-level data from three more, no time-trend in survival 2012 to 2022. 4. "Confirming that the target was successfully drugged or edited or both." (line 31) ✓ Platform evidence documented; product-specific bridge required. After DC vaccination, cytotoxic T cells increased inside the tumor, and infiltration correlated with survival (P = 0.047); T cell infiltration in the UCLA vaccine-first arm. The FDA is open to confirmation "for a subset of patients"; the BLA should supply DCVax-L's own immune-monitoring results and the bridge to these studies. 5. "Demonstrating improvement in clinical outcomes or course." (line 32) ✓ Met: longer survival, five-year survival more than doubled, a bigger benefit under patient-level matching. The eight considerations attached, each answered: 1. An individualized therapy aimed at "a specific pathophysiologic abnormality" 2. A "compensatory mechanism with a clear mechanistic rationale" 3. Substantial evidence from "a single adequate and well-controlled clinical investigation with confirmatory evidence" 4. A natural history that lets the effect be "reasonably distinguished from natural variability" 5. An improvement not attributable to "alternative treatments or natural variability" 6. Prespecified analysis plans 7. A reason a new RCT is not feasible 8. A product that "can be manufactured to regulatory quality standards," made for every phase 3 patient: manufacturing experience documented, US CMC review required 13 of 13, every one in the FDA's own words, every one answered from the record, every open step named. 𝗧𝗵𝗲 𝗰𝗼𝗻𝗳𝗶𝗿𝗺𝗮𝘁𝗼𝗿𝘆 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲, 𝗶𝗻 𝘁𝗵𝗲 𝗙𝗗𝗔'𝘀 𝗼𝘄𝗻 𝗰𝗮𝘁𝗲𝗴𝗼𝗿𝗶𝗲𝘀 Mechanism: in the DCVax-Direct phase 1 (a different product: activated dendritic cells injected into diverse solid tumors), more IL-8 and IL-12p40 from each patient's cells went with longer survival, p=0.023 and 0.024. Exposure-response, in the FDA's words. Related product: UCLA's 46-patient randomized phase 1 trial of its own tumor lysate DC vaccine, at EANO this Friday. Both arms got the vaccine; the order was randomized. Vaccine first, 555 days. Checkpoint first, 271. HR 0.32. The order matters: priming before checkpoint release more than doubled median survival. Across the class, a 2024 meta-analysis of seven dendritic cell vaccine trials, 3,619 patients, found HR 0.71 for survival, "indicating a true-positive result." Related indication: the FDA's own example is "a different stage of the same disease." DCVax-L worked at both stages. Independent natural history: national cancer registries, separate from the trial controls, as the guidance requires. Real-world data is expressly allowed. 𝗧𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗰𝗿𝗶𝘁𝗶𝗰𝗶𝘀𝗺𝘀, 𝗮𝗻𝘀𝘄𝗲𝗿𝗲𝗱 Three published critiques set out the case against the trial. Each point, answered from the record: Endpoint switched to survival? Progression could not be read: 256 of 494 scans needed adjudication. The critics agree: progression-free survival "is not an adequate endpoint for immunotherapy studies because of the phenomenon of pseudoprogression." Survival is the "gold standard," in their words. Cohort-level controls? The critics named the fix: propensity score matching or inverse probability weighting on patient-level data. That is exactly what 2026 did, and the benefit grew. Never validated in GBM? Two of the critics who raised it led the 2026 study showing patient-level external controls reproduce randomized results. Selection? Dropping the control trials that admitted early progressors changed nothing, as above. The benefit was larger in patients with more residual tumor, the opposite of what selection would produce. IDH, a tumor mutation linked to longer survival? Tested centrally in every DCVax-L patient. The gap is in the older control trials. Chosen after the fact? An independent firm, prespecified criteria, validation as above. Then a larger effect against different trials at the patient level. Company author? Data held by independent CROs, analyzed by independent statisticians. Run another trial? The completed program, crossover and survival evidence make a repeat unnecessary; the FDA's guidance names the ethical concern; the BLA documents why a new randomized design is not feasible or ethical. 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 The framework also requires that the product "can be manufactured to regulatory quality standards." DCVax-L was made for every patient in a 94-site phase 3, and in 2023 the UK regulator licensed the Sawston facility for commercial manufacturing, with products that "may be exported globally." A UK license is not US approval: FDA inspection and the potency assay go on the table at the pre-BLA meeting. 𝗕𝗲𝗻𝗲𝗳𝗶𝘁 𝗮𝗻𝗱 𝗿𝗶𝘀𝗸 Longer survival in a disease with no proven alternative at recurrence. 2,151 doses, 5 serious events even possibly related, no autoimmunity, no cytokine storm. It is the patient's own immune system, with one broken link rebuilt. A repair, judged the way a repair should be judged. 𝗧𝗿𝗲𝗮𝘁𝗶𝗻𝗴 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗵𝗶𝗹𝗲 𝘁𝗵𝗲 𝗙𝗗𝗔 𝗿𝗲𝘃𝗶𝗲𝘄𝘀 Right to Try covers a product that has completed phase 1, is in active development and not on hold, and has an application on file. Filing the BLA satisfies the application condition; the others must still hold at that time. Patients must have a life-threatening disease, have exhausted approved treatments, be unable to join a trial and consent, and the manufacturer must choose to provide it. No separate FDA approval of each case. Build the program before filing. An expanded access treatment protocol (21 CFR 312.320) requires completed trials, active pursuit of approval and phase 3 evidence. The trials are complete and the phase 3 is published, so it does not have to wait for the BLA. Treatment can begin 30 days after the FDA receives the protocol, absent a hold. The usual reason a manufacturer holds back is risk: a serious event in a very sick patient gets blamed on the product. The FDA answered that in its April 2026 guidance: it "does not intend to deny, delay, or refuse to approve" a BLA "based solely on an adverse event occurring in the context of expanded access use," and "is not aware of any instances" where one prevented approval. Access is the bridge. Approval is the destination. This is not new for DCVax-L: it has been provided under Germany's hospital exemption and the UK Specials pathway. 𝗦𝗲𝗲𝗸 𝘁𝗿𝗮𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹, 𝘄𝗶𝘁𝗵 𝗮 𝗽𝗿𝗼𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝗱𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝘆 The framework's guidance: approval is traditional or accelerated "depending on the endpoints used." Survival is the endpoint, so the request is traditional, full approval, with no confirmatory-trial requirement. The FDA can still require postmarketing studies, and the framework's authors named the tool: "collecting real-world evidence to confirm continued preservation of efficacy." A registry of every treated patient, designed before approval. If accelerated approval becomes the route, the regenerative medicine advanced therapy (RMAT) statute lets post-approval requirements be met through registries and "postapproval monitoring of all patients treated with such therapy prior to approval." Every patient treated under Right to Try or expanded access counts. 𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝗻𝗲𝘅𝘁 Northwest has pursued the UK first. Its application there has been under review since late 2023, and in July 2026 the UK regulator confirmed it "remains under its initial regulatory review, has not been refused." The US filing is the step that remains. 1. Publish the patient-level reanalysis. 2. Lock in the patient-level control data rights the FDA requires. 3. Report the central IDH results and publish the phase 3 immune data. 4. Request RMAT designation now. FDA must answer within 60 days. 5. File the treatment protocol and build the Right to Try program. 6. Pre-BLA meeting with CBER: plausible mechanism review, six external-control tests answered, manufacturing and potency package. 7. File the BLA with priority review. 8. Build the registry. Approving DCVax-L this way would be the framework's proof beyond genetic disease: an individualized cell therapy, aimed at the root cause of the deadliest brain cancer, carried by a completed phase 3. A win for patients first. 𝗧𝗵𝗲 𝘁𝗿𝗶𝗮𝗹 𝗶𝘀 𝗱𝗼𝗻𝗲. 𝗧𝗵𝗲 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 𝗶𝘀 𝘄𝗿𝗶𝘁𝘁𝗲𝗻. 𝗧𝗵𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗮𝗿𝗲 𝘄𝗮𝗶𝘁𝗶𝗻𝗴. 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗹𝗲𝗳𝘁 𝗶𝘀 𝘁𝗼 𝗮𝘀𝘀𝗲𝗺𝗯𝗹𝗲 𝗶𝘁 𝗮𝗻𝗱 𝗳𝗶𝗹𝗲. Disclosure: long $NWBO. Commentary on published and presented data and public FDA documents. Not medical, legal, regulatory or investment advice. DCVax-L is investigational and not approved in the US. Regulatory strategy is the sponsor's decision.
8:19

𝗧𝗵𝗲 $NWBO 𝗗𝗖𝗩𝗮𝘅-𝗟 𝘁𝗿𝗶𝗮𝗹 𝗶𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗱𝗼𝗻𝗲. 𝗧𝗵𝗲 𝗙𝗗𝗔 𝗵𝗮𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝘄𝗿𝗶𝘁𝘁𝗲𝗻 𝘁𝗵𝗲 𝗽𝗹𝗮𝘂𝘀𝗶𝗯𝗹𝗲 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝗽𝗮𝘁𝗵𝘄𝗮𝘆. 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗹𝗲𝗳𝘁 𝗶𝘀 𝘁𝗼 𝗮𝘀𝘀𝗲𝗺𝗯𝗹𝗲 𝗶𝘁 𝗮𝗻𝗱 𝗳𝗶𝗹𝗲. #DCVax-L is a vaccine made for each patient from their own dendritic cells, the immune cells that teach the rest of the immune system what to attack, loaded with their own tumor. It treats #glioblastoma, the deadliest brain cancer. An American company developed it, yet Americans have to go to Europe to get it. #DCVaxForBraelyn The FDA has spent the past year writing down how it wants to judge treatments like this one. The core evidence it asks for already exists. One question decides this: can the FDA evaluate DCVax-L for approval under the plausible mechanism framework, on the evidence already generated? Read against every document the agency has published on the framework, the answer is yes. 𝗧𝗵𝗲 𝗽𝗹𝗮𝗻 𝗶𝗻 𝘁𝗵𝗿𝗲𝗲 𝘀𝘁𝗲𝗽𝘀 1. File the biologics license application (BLA) and ask the FDA's biologics center (CBER) for review under the plausible mechanism framework. A BLA is not another trial. It is the dossier the FDA decides on, and the framework changes what counts as sufficient inside it. The framework itself needs no new statute and no special designation. A sponsor asks for it. 2. Ask for full approval on survival, with no new randomized trial. The completed phase 3 is the pivotal study. Mechanism, a related product, a related stage of the disease and independent natural history are the confirmatory evidence. A registry of every treated patient supplies the follow-up. 3. Open access alongside the filing. An expanded access treatment protocol does not have to wait for the BLA; it can begin 30 days after the FDA receives it. Filing the BLA satisfies Right to Try's application condition. 𝗪𝗵𝗮𝘁 𝘁𝗵𝗲 𝗙𝗗𝗔 𝗵𝗮𝘀 𝘄𝗿𝗶𝘁𝘁𝗲𝗻 𝗱𝗼𝘄𝗻 Nov 2025, NEJM, Prasad and Makary: the plausible mechanism framework. Five questions. Built for cell and gene therapies first, and available for common diseases, particularly those "for which there are no proven alternative treatments." Feb 2026, NEJM: one adequate and well-controlled study plus confirmatory evidence is the FDA's default basis for approval. Feb 2026 draft guidance: an externally controlled study against a well-characterized natural history can be the pivotal study. Confirmatory evidence includes mechanism, target engagement and "exposure-response on biomarkers and clinical outcomes." The product can target "a well-characterized downstream or compensatory mechanism with a clear mechanistic rationale." June 2026 draft guidance: six conditions under which an external control supports effectiveness. The plausible mechanism framework named as an example of FDA regulatory flexibility in critical settings. "Even small effects may be clinically meaningful when the effect is on survival or irreversible morbidity." Why it exists: to bring regulatory flexibility to individualized therapies where the conventional model does not fit. The guidance names gene and RNA therapies, then says "the general concepts may apply to other types of individualized therapies": therapies that target "a specific pathophysiologic abnormality serving as the root cause of a disease." The FDA's own announcement: the guidance "leaves open the potential that this framework may apply to additional tailored therapeutics provided they directly address the underlying specific cause of the disease." The framework is not a new approval standard. It is how the FDA reads evidence under the standard that already exists. That is exactly why it can be asked for today. 𝗪𝗵𝘆 𝗴𝗹𝗶𝗼𝗯𝗹𝗮𝘀𝘁𝗼𝗺𝗮 𝗶𝘀 𝘁𝗵𝗲 𝗰𝗮𝘀𝗲 𝗶𝘁 𝘄𝗮𝘀 𝘄𝗿𝗶𝘁𝘁𝗲𝗻 𝗳𝗼𝗿 No proven alternative: recurrent GBM has no established standard of care. Of 400+ trials since 2005, only one phase 3 in newly diagnosed and none in recurrent disease had shown a survival benefit. High and predictable mortality: the exact case FDA regulations name for historical controls, "certain malignancies." Life-threatening in the regulation's own terms: a disease "where the end point of clinical trial analysis is survival." Individualized: a different product for every patient, made from their own cells and their own tumor, aimed at the root cause, the broken instruction layer. Orphan designation in the US and Europe. 𝗧𝗵𝗲 𝗽𝗶𝘃𝗼𝘁𝗮𝗹 𝘀𝘁𝘂𝗱𝘆 𝗶𝘀 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 331 patients, 94 sites, randomized, double blind. 64 of 99 placebo patients crossed over at recurrence, so survival was measured against 2,006 contemporaneous matched control patients from 15 randomized trials. Newly diagnosed: 19.3 vs 16.5 months, HR 0.80, p=.002. Alive at 5 years: 13.0% vs 5.7%. Recurrent: 13.2 vs 7.8 months, HR 0.58, p<.001. That is a 42% lower risk of death. The benefit widened over time, and it was largest in the patients who fare worst. Why no second trial? The completed trial, the crossover and the survival evidence make the case, and the FDA's June guidance names the ethical stake: after "a substantial decrease in mortality," a second trial "would generally present significant ethical concerns." 𝗧𝗵𝗲 𝟮𝟬𝟮𝟲 𝗿𝗲𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 The phase 3 paper named its own limitation: without patient-level control data, "propensity score matching could not be performed." The critics named the missing methods: "propensity score matching or inverse probability weighting." In 2026 Northwest obtained individual patient data from three independent randomized trials and had independent statisticians run exactly those two methods. Propensity score matching pairs each DCVax-L patient with control patients who had the same prognostic profile, so like is compared with like. Presented at BNOS in July 2026; peer-reviewed publication is the next step. Propensity score matching: HR 0.69 to 0.77. Median survival +3.4 to +6.3 months. p .004 to .027. The original cohort-level analysis showed +2.8. When the matching got finer, the benefit got bigger. The survival advantage held under both patient-level methods and was larger than the original cohort-level estimate. Northwest reports sensitivity analyses for hidden confounding; the published paper should give the values. The method has been tested in this exact disease. In May 2026, the INSIGhT investigators replaced their own randomized control arm with propensity-matched external controls. For three drugs that had failed randomized testing, the method also found no benefit: HR 1.00, 0.93, 0.88. "Carefully matched external controls" produced "treatment effect estimates that were similar" to the randomized analyses. The method did not invent a benefit. Applied to DCVax-L, it found one. And the authorship closes the loop. In 2023, Dana-Farber statisticians Rahman, Ventz and Trippa wrote that they were "not aware of independent validations of these analytic methods in a GBM trial context." Rahman and Trippa are the senior authors of the 2026 INSIGhT validation. The critics asked for patient-level data and a validated method. By 2026 both existed. That supports the method the DCVax-L reanalysis used; publishing that analysis in full is step one. And it is the form a BLA requires: FDA guidance says applications "must include" patient-level data for the external control arm. 𝗧𝗵𝗲 𝗙𝗗𝗔'𝘀 𝘀𝗶𝘅 𝘁𝗲𝘀𝘁𝘀 𝗳𝗼𝗿 𝗮𝗻 𝗲𝘅𝘁𝗲𝗿𝗻𝗮𝗹 𝗰𝗼𝗻𝘁𝗿𝗼𝗹, 𝗮𝗻𝘀𝘄𝗲𝗿𝗲𝗱 1. Well-defined natural history: 2,006 controls from 15 randomized trials. 2. Very similar populations: 14 prespecified criteria, chosen by an independent firm, validated against all 15 source trials, now matched patient by patient. 3. Similar treatments: in newly diagnosed disease, surgery, radiation and temozolomide in both groups. 4. Objective endpoint: death. 5. Comparable start: survival from randomization after radiotherapy in both groups. Drop the two control trials that admitted early progressors: HR still 0.80. 6. An effect too large to be bias: five-year survival more than doubled, HR 0.58 at recurrence, and the effect grew when matching tightened. 𝗧𝗵𝗲 𝗽𝗹𝗮𝘂𝘀𝗶𝗯𝗹𝗲 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝗰𝗿𝗶𝘁𝗲𝗿𝗶𝗮, 𝘄𝗼𝗿𝗱 𝗳𝗼𝗿 𝘄𝗼𝗿𝗱 The FDA's five elements, quoted exactly from its February 2026 draft guidance ( lines 26 to 32), each answered: 1. "Identifying a specific genetic, cellular, or molecular abnormality with a clear connection between specific alteration and disease indication." (line 26) ✓ Met: in GBM, the dendritic cells that should teach T cells what to attack are overridden by suppressive immune cells. A tumor never presented for attack grows unopposed. 2. "Developing a therapy that targets the underlying or proximate pathogenic biological alterations." (line 28) ✓ Met: DCVax-L supplies the patient's own dendritic cells, loaded with their own tumor and prepared outside the suppressive tumor environment, to restore tumor-directed T-cell instruction. 3. "Relying on a well-characterized natural history of the disease in an untreated population." (line 30) ✓ Met: 2,006 controls from 15 randomized trials, patient-level data from three more, no time-trend in survival 2012 to 2022. 4. "Confirming that the target was successfully drugged or edited or both." (line 31) ✓ Platform evidence documented; product-specific bridge required. After DC vaccination, cytotoxic T cells increased inside the tumor, and infiltration correlated with survival (P = 0.047); T cell infiltration in the UCLA vaccine-first arm. The FDA is open to confirmation "for a subset of patients"; the BLA should supply DCVax-L's own immune-monitoring results and the bridge to these studies. 5. "Demonstrating improvement in clinical outcomes or course." (line 32) ✓ Met: longer survival, five-year survival more than doubled, a bigger benefit under patient-level matching. The eight considerations attached, each answered: 1. An individualized therapy aimed at "a specific pathophysiologic abnormality" 2. A "compensatory mechanism with a clear mechanistic rationale" 3. Substantial evidence from "a single adequate and well-controlled clinical investigation with confirmatory evidence" 4. A natural history that lets the effect be "reasonably distinguished from natural variability" 5. An improvement not attributable to "alternative treatments or natural variability" 6. Prespecified analysis plans 7. A reason a new RCT is not feasible 8. A product that "can be manufactured to regulatory quality standards," made for every phase 3 patient: manufacturing experience documented, US CMC review required 13 of 13, every one in the FDA's own words, every one answered from the record, every open step named. 𝗧𝗵𝗲 𝗰𝗼𝗻𝗳𝗶𝗿𝗺𝗮𝘁𝗼𝗿𝘆 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲, 𝗶𝗻 𝘁𝗵𝗲 𝗙𝗗𝗔'𝘀 𝗼𝘄𝗻 𝗰𝗮𝘁𝗲𝗴𝗼𝗿𝗶𝗲𝘀 Mechanism: in the DCVax-Direct phase 1 (a different product: activated dendritic cells injected into diverse solid tumors), more IL-8 and IL-12p40 from each patient's cells went with longer survival, p=0.023 and 0.024. Exposure-response, in the FDA's words. Related product: UCLA's 46-patient randomized phase 1 trial of its own tumor lysate DC vaccine, at EANO this Friday. Both arms got the vaccine; the order was randomized. Vaccine first, 555 days. Checkpoint first, 271. HR 0.32. The order matters: priming before checkpoint release more than doubled median survival. Across the class, a 2024 meta-analysis of seven dendritic cell vaccine trials, 3,619 patients, found HR 0.71 for survival, "indicating a true-positive result." Related indication: the FDA's own example is "a different stage of the same disease." DCVax-L worked at both stages. Independent natural history: national cancer registries, separate from the trial controls, as the guidance requires. Real-world data is expressly allowed. 𝗧𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗰𝗿𝗶𝘁𝗶𝗰𝗶𝘀𝗺𝘀, 𝗮𝗻𝘀𝘄𝗲𝗿𝗲𝗱 Three published critiques set out the case against the trial. Each point, answered from the record: Endpoint switched to survival? Progression could not be read: 256 of 494 scans needed adjudication. The critics agree: progression-free survival "is not an adequate endpoint for immunotherapy studies because of the phenomenon of pseudoprogression." Survival is the "gold standard," in their words. Cohort-level controls? The critics named the fix: propensity score matching or inverse probability weighting on patient-level data. That is exactly what 2026 did, and the benefit grew. Never validated in GBM? Two of the critics who raised it led the 2026 study showing patient-level external controls reproduce randomized results. Selection? Dropping the control trials that admitted early progressors changed nothing, as above. The benefit was larger in patients with more residual tumor, the opposite of what selection would produce. IDH, a tumor mutation linked to longer survival? Tested centrally in every DCVax-L patient. The gap is in the older control trials. Chosen after the fact? An independent firm, prespecified criteria, validation as above. Then a larger effect against different trials at the patient level. Company author? Data held by independent CROs, analyzed by independent statisticians. Run another trial? The completed program, crossover and survival evidence make a repeat unnecessary; the FDA's guidance names the ethical concern; the BLA documents why a new randomized design is not feasible or ethical. 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 The framework also requires that the product "can be manufactured to regulatory quality standards." DCVax-L was made for every patient in a 94-site phase 3, and in 2023 the UK regulator licensed the Sawston facility for commercial manufacturing, with products that "may be exported globally." A UK license is not US approval: FDA inspection and the potency assay go on the table at the pre-BLA meeting. 𝗕𝗲𝗻𝗲𝗳𝗶𝘁 𝗮𝗻𝗱 𝗿𝗶𝘀𝗸 Longer survival in a disease with no proven alternative at recurrence. 2,151 doses, 5 serious events even possibly related, no autoimmunity, no cytokine storm. It is the patient's own immune system, with one broken link rebuilt. A repair, judged the way a repair should be judged. 𝗧𝗿𝗲𝗮𝘁𝗶𝗻𝗴 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗵𝗶𝗹𝗲 𝘁𝗵𝗲 𝗙𝗗𝗔 𝗿𝗲𝘃𝗶𝗲𝘄𝘀 Right to Try covers a product that has completed phase 1, is in active development and not on hold, and has an application on file. Filing the BLA satisfies the application condition; the others must still hold at that time. Patients must have a life-threatening disease, have exhausted approved treatments, be unable to join a trial and consent, and the manufacturer must choose to provide it. No separate FDA approval of each case. Build the program before filing. An expanded access treatment protocol (21 CFR 312.320) requires completed trials, active pursuit of approval and phase 3 evidence. The trials are complete and the phase 3 is published, so it does not have to wait for the BLA. Treatment can begin 30 days after the FDA receives the protocol, absent a hold. The usual reason a manufacturer holds back is risk: a serious event in a very sick patient gets blamed on the product. The FDA answered that in its April 2026 guidance: it "does not intend to deny, delay, or refuse to approve" a BLA "based solely on an adverse event occurring in the context of expanded access use," and "is not aware of any instances" where one prevented approval. Access is the bridge. Approval is the destination. This is not new for DCVax-L: it has been provided under Germany's hospital exemption and the UK Specials pathway. 𝗦𝗲𝗲𝗸 𝘁𝗿𝗮𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹, 𝘄𝗶𝘁𝗵 𝗮 𝗽𝗿𝗼𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝗱𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝘆 The framework's guidance: approval is traditional or accelerated "depending on the endpoints used." Survival is the endpoint, so the request is traditional, full approval, with no confirmatory-trial requirement. The FDA can still require postmarketing studies, and the framework's authors named the tool: "collecting real-world evidence to confirm continued preservation of efficacy." A registry of every treated patient, designed before approval. If accelerated approval becomes the route, the regenerative medicine advanced therapy (RMAT) statute lets post-approval requirements be met through registries and "postapproval monitoring of all patients treated with such therapy prior to approval." Every patient treated under Right to Try or expanded access counts. 𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝗻𝗲𝘅𝘁 Northwest has pursued the UK first. Its application there has been under review since late 2023, and in July 2026 the UK regulator confirmed it "remains under its initial regulatory review, has not been refused." The US filing is the step that remains. 1. Publish the patient-level reanalysis. 2. Lock in the patient-level control data rights the FDA requires. 3. Report the central IDH results and publish the phase 3 immune data. 4. Request RMAT designation now. FDA must answer within 60 days. 5. File the treatment protocol and build the Right to Try program. 6. Pre-BLA meeting with CBER: plausible mechanism review, six external-control tests answered, manufacturing and potency package. 7. File the BLA with priority review. 8. Build the registry. Approving DCVax-L this way would be the framework's proof beyond genetic disease: an individualized cell therapy, aimed at the root cause of the deadliest brain cancer, carried by a completed phase 3. A win for patients first. 𝗧𝗵𝗲 𝘁𝗿𝗶𝗮𝗹 𝗶𝘀 𝗱𝗼𝗻𝗲. 𝗧𝗵𝗲 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 𝗶𝘀 𝘄𝗿𝗶𝘁𝘁𝗲𝗻. 𝗧𝗵𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗮𝗿𝗲 𝘄𝗮𝗶𝘁𝗶𝗻𝗴. 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗹𝗲𝗳𝘁 𝗶𝘀 𝘁𝗼 𝗮𝘀𝘀𝗲𝗺𝗯𝗹𝗲 𝗶𝘁 𝗮𝗻𝗱 𝗳𝗶𝗹𝗲. Disclosure: long $NWBO. Commentary on published and presented data and public FDA documents. Not medical, legal, regulatory or investment advice. DCVax-L is investigational and not approved in the US. Regulatory strategy is the sponsor's decision.

Andrew Caravello, DO

46,627 просмотров • 6 дней назад

The Cost of Neglect: Family, Priorities, and the Loneliness of Old Age A video features a doctor running a cardiac clinic recounting the story of a 75-year-old woman who broke down in tears after receiving test results confirming a chronic illness that may require referral for possible surgery. She was not crying because of the medical prognosis itself. She wept because no one in her family had made time to accompany her to the clinic for her consultations. In stark contrast, another patient had her children and extended kin fully involved - handling paperwork, payments, and all necessary support. We now stand at a familiar crossroads where the choices we make as partners, parents, siblings, and friends collide with harsh reality. In our younger, productive years, life’s priorities are often dictated by external forces. Many never spend meaningful weekends with their children, instead pouring time and resources into church activities, chama (investment groups), expensive hobbies like golf, or chasing career fulfillment and business goals. Without striking a healthy balance, all of it ultimately proves null and void. From a broader perspective, this personal neglect is also the culmination of years of voter apathy and political indifference. Mainstream media influence, religious institutions, and widespread political illiteracy have repeatedly led people - particularly women, who are often at the forefront of elections - to support the same looters of public funds, including health sector resources. We witnessed “Mama Mboga” being mobilized to vote for Ruto while dancing to “Tugokira Tene,” and women electing Sakaja Johnson largely because of his dimples, among other examples. This chronic pattern carries a heavy cost, and sympathy for such outcomes is increasingly scarce. Here are practical tips for those who wish to avoid this trap of isolation in later life: Never miss your partner’s, children’s, relatives and close friends milestone moments - birthdays, school functions, and other key events. On Sundays, limit church activities to no more than one hour. Because the rat race dominates the first five days of the week, Saturday and Sunday represent your only real window for balance. You cannot repeat the same activity across both weekend days. For instance: • You cannot leave your family to play golf two days in a row - that is a recipe for disaster. • You cannot devote the entire weekend to church activities and still expect your family to sacrifice their time for you in the future. • You cannot watch EPL matches with the boys both days and assume your wife and children will happily celebrate your absence. • You cannot attend chama events with different groups of friends every weekend and expect them to be there for you in old age. Choose wisely. Spread your commitments out. Attend to everything within a balanced program. Review your schedule and prioritize those most likely to show up for you in times of uncertainty - then work backwards from there. You cannot hide behind Bible verses like Ephesians while having lived a life of indifference and unavailability - always “busy,” constantly out of town, never truly fellowshipping with friends and family - yet expecting them to drop everything when you need care. That era is long gone. How to Prioritize Your Time: 1. Your partner comes first. Forget what feminists or red-pill radicalists claim - they will not be the ones taking you to the hospital when you are sick. 2. Your children come second. Dedicate one full day (either Saturday or Sunday) entirely to them. 3. Circle of close friends - Monthly meetups, occasional drinks, or chama activities, kept within a time-restricted structure. 4. Community obligations - Weddings, ruracios, maombolezi, funerals, etc. 5. Hobbies - EPL, golf, road trips, and similar pursuits. 6. Church - Placed last in the hierarchy of regular commitments.
1:48

The Cost of Neglect: Family, Priorities, and the Loneliness of Old Age A video features a doctor running a cardiac clinic recounting the story of a 75-year-old woman who broke down in tears after receiving test results confirming a chronic illness that may require referral for possible surgery. She was not crying because of the medical prognosis itself. She wept because no one in her family had made time to accompany her to the clinic for her consultations. In stark contrast, another patient had her children and extended kin fully involved - handling paperwork, payments, and all necessary support. We now stand at a familiar crossroads where the choices we make as partners, parents, siblings, and friends collide with harsh reality. In our younger, productive years, life’s priorities are often dictated by external forces. Many never spend meaningful weekends with their children, instead pouring time and resources into church activities, chama (investment groups), expensive hobbies like golf, or chasing career fulfillment and business goals. Without striking a healthy balance, all of it ultimately proves null and void. From a broader perspective, this personal neglect is also the culmination of years of voter apathy and political indifference. Mainstream media influence, religious institutions, and widespread political illiteracy have repeatedly led people - particularly women, who are often at the forefront of elections - to support the same looters of public funds, including health sector resources. We witnessed “Mama Mboga” being mobilized to vote for Ruto while dancing to “Tugokira Tene,” and women electing Sakaja Johnson largely because of his dimples, among other examples. This chronic pattern carries a heavy cost, and sympathy for such outcomes is increasingly scarce. Here are practical tips for those who wish to avoid this trap of isolation in later life: Never miss your partner’s, children’s, relatives and close friends milestone moments - birthdays, school functions, and other key events. On Sundays, limit church activities to no more than one hour. Because the rat race dominates the first five days of the week, Saturday and Sunday represent your only real window for balance. You cannot repeat the same activity across both weekend days. For instance: • You cannot leave your family to play golf two days in a row - that is a recipe for disaster. • You cannot devote the entire weekend to church activities and still expect your family to sacrifice their time for you in the future. • You cannot watch EPL matches with the boys both days and assume your wife and children will happily celebrate your absence. • You cannot attend chama events with different groups of friends every weekend and expect them to be there for you in old age. Choose wisely. Spread your commitments out. Attend to everything within a balanced program. Review your schedule and prioritize those most likely to show up for you in times of uncertainty - then work backwards from there. You cannot hide behind Bible verses like Ephesians while having lived a life of indifference and unavailability - always “busy,” constantly out of town, never truly fellowshipping with friends and family - yet expecting them to drop everything when you need care. That era is long gone. How to Prioritize Your Time: 1. Your partner comes first. Forget what feminists or red-pill radicalists claim - they will not be the ones taking you to the hospital when you are sick. 2. Your children come second. Dedicate one full day (either Saturday or Sunday) entirely to them. 3. Circle of close friends - Monthly meetups, occasional drinks, or chama activities, kept within a time-restricted structure. 4. Community obligations - Weddings, ruracios, maombolezi, funerals, etc. 5. Hobbies - EPL, golf, road trips, and similar pursuits. 6. Church - Placed last in the hierarchy of regular commitments.

Francis Gaitho

20,391 просмотров • 4 месяцев назад

My fox shooting garden defending AI robot is finally done and WORKING! 🤩 (Don’t worry it only shoots 💦 water) After months of slowly moving forward with each part I finished the last step to train a TensorFlow model on the footage of the 🦊 fox I collected hours of footage 📹 with the fox roaming around my garden, from this I labeled around 2000 images with the fox by hand ✋ Honestly, I was quite skeptical training the model was actually gonna work, maybe this was partly the reason I avoided working on this until the very end. If I couldn’t train a model to detect the fox, this whole robot would never be able to function properly. On the flipside though, with no previous experience in hardware or electronics there was a bit of a learning curve and I didn’t want to end up labeling thousands of images, training a TensorFlow model, only to fail on building the hardware. As I started building, I realized that mixing hardware and software adds quite another dimension to debugging things. At times I wasted hours debugging code in my IDE, only to realize the issue was somewhere in the electronics. Furthermore, combining this side project with a full time job and a young family, is not always easy. It can be quite frustrating, to know you only need 4 hours of concentrated effort for a small task, having to spread it out across a week of 20min increments. Then, a few months into the build I noticed the fox had stopped coming to my garden, in fact one day, I recorded her walking with 3 cute little 🐶 pups, and the next day I saw her moving out of my garden completely. Did she know I was building a robot? I had this strange mix of feelings, happy my garden was safe from poop and digging, happy she was safe with her pups, but how was I gonna finish this project if my robot had no fox to detect? For sure they would be back next year, I figured I could postpone the whole thing until next winter, but I also knew it was gonna be much harder to pick up momentum if I did let it sit there for six months. So I decided to keep working, hoping the fox would reappear,.. but she never did. As I finished labeling the footage and started training my model, I could finally see the mAP results, quantifying the precision of my object detection model. It was measuring at 78% across different metrics on detecting my fox. I quickly ran the model on some of the video footage I got from my fox. Inference speed took a hit, but it did a near perfect job detecting the fox, even when she was deep down in the grass or wizzing past in a motion blur. It took me by surprise how well it worked. With the default model I had to drop my confidence threshold way down to 15%, to recognize the fox as 🦜“bird” in one or two frames, with my custom model it followed the fox all the way down to the back of the garden! Still this didn’t solve the issue of there being no actual fox in my garden and how was I gonna wrap this project in a short timeframe. I played with the idea of putting a fox toy 🧸 on an RC 🚗 car, or borrowing a dog to run around the garden to test. Friends suggested I run around the garden in a fox costume.. what a ridiculous idea. I wasn’t really feeling the idea of running around the garden in a floppy cloth fox 🎭 costume, but had a look anyway. I came across these self inflating costumes. This actually could be perfect. Since it’s inflated, it would hold its shape super well, making it much easier to label, train and be recognized by my robot. So I got the costume and shot a time lapse of myself as a fox walking around the garden. I labeled it to around 600 images. Ran the model training again and got a mAP result of 82%. This was even better than my real fox! At this point I knew this was gonna work. So here’s the final 🎥 video, just having some fun with it. I’ll update here whenever the real fox does come back. On a final note, I’m looking for (remote) jobs in these fields of AI now: - object detection - visual generative AI - 3D (nerfs + gaussian splats) So if you know anything let me know! My DMs are open 😊
2:05

My fox shooting garden defending AI robot is finally done and WORKING! 🤩 (Don’t worry it only shoots 💦 water) After months of slowly moving forward with each part I finished the last step to train a TensorFlow model on the footage of the 🦊 fox I collected hours of footage 📹 with the fox roaming around my garden, from this I labeled around 2000 images with the fox by hand ✋ Honestly, I was quite skeptical training the model was actually gonna work, maybe this was partly the reason I avoided working on this until the very end. If I couldn’t train a model to detect the fox, this whole robot would never be able to function properly. On the flipside though, with no previous experience in hardware or electronics there was a bit of a learning curve and I didn’t want to end up labeling thousands of images, training a TensorFlow model, only to fail on building the hardware. As I started building, I realized that mixing hardware and software adds quite another dimension to debugging things. At times I wasted hours debugging code in my IDE, only to realize the issue was somewhere in the electronics. Furthermore, combining this side project with a full time job and a young family, is not always easy. It can be quite frustrating, to know you only need 4 hours of concentrated effort for a small task, having to spread it out across a week of 20min increments. Then, a few months into the build I noticed the fox had stopped coming to my garden, in fact one day, I recorded her walking with 3 cute little 🐶 pups, and the next day I saw her moving out of my garden completely. Did she know I was building a robot? I had this strange mix of feelings, happy my garden was safe from poop and digging, happy she was safe with her pups, but how was I gonna finish this project if my robot had no fox to detect? For sure they would be back next year, I figured I could postpone the whole thing until next winter, but I also knew it was gonna be much harder to pick up momentum if I did let it sit there for six months. So I decided to keep working, hoping the fox would reappear,.. but she never did. As I finished labeling the footage and started training my model, I could finally see the mAP results, quantifying the precision of my object detection model. It was measuring at 78% across different metrics on detecting my fox. I quickly ran the model on some of the video footage I got from my fox. Inference speed took a hit, but it did a near perfect job detecting the fox, even when she was deep down in the grass or wizzing past in a motion blur. It took me by surprise how well it worked. With the default model I had to drop my confidence threshold way down to 15%, to recognize the fox as 🦜“bird” in one or two frames, with my custom model it followed the fox all the way down to the back of the garden! Still this didn’t solve the issue of there being no actual fox in my garden and how was I gonna wrap this project in a short timeframe. I played with the idea of putting a fox toy 🧸 on an RC 🚗 car, or borrowing a dog to run around the garden to test. Friends suggested I run around the garden in a fox costume.. what a ridiculous idea. I wasn’t really feeling the idea of running around the garden in a floppy cloth fox 🎭 costume, but had a look anyway. I came across these self inflating costumes. This actually could be perfect. Since it’s inflated, it would hold its shape super well, making it much easier to label, train and be recognized by my robot. So I got the costume and shot a time lapse of myself as a fox walking around the garden. I labeled it to around 600 images. Ran the model training again and got a mAP result of 82%. This was even better than my real fox! At this point I knew this was gonna work. So here’s the final 🎥 video, just having some fun with it. I’ll update here whenever the real fox does come back. On a final note, I’m looking for (remote) jobs in these fields of AI now: - object detection - visual generative AI - 3D (nerfs + gaussian splats) So if you know anything let me know! My DMs are open 😊

Jeroen Pixel

55,797 просмотров • 2 лет назад

Two things happened today that made my heart full. First — I officially graduated as a DM in Clinical Immunology and Rheumatology from the prestigious Christian Medical College, Vellore. Second — I received the Dr. Debashish Danda Memorial Best Outgoing Student Medal. Two moments. One dream. A journey that began years ago in quiet classrooms and long, sleepless nights — and ended today in the glow of gratitude. I come from a family with no medical background. From Calicut Medical College, to TD Medical College, and finally to CMC Vellore — the path was long, uncertain, and often lonely. When I first decided to pursue rheumatology, it wasn’t a calculated choice — it was a feeling, a hunch that this was my cup of tea. I walked into this field thinking rheumatology would be more close to medicine — the one I loved and wanted to be with — even though I hadn’t seen many rheumatology patients before. But CMC taught me the truth. Every single day was a whirlwind of patients — in the OPD, in the wards, in casualty. Every disease I had once read about in Harrison’s now stood before me — not as lines in a textbook, but as human stories. I saw suffering and resilience, fear and hope, silence and strength — all living together in the same faces. And when a patient smiled again after months of pain, that smile carried more meaning than any medal or title ever could. Our HOD once told us something I’ll never forget: “In rheumatology, care is like aiming with a bow — the farther you pull back, the farther your arrow of compassion and understanding will go.” He meant that true care is not just about prescribing drugs — it’s about listening, counselling, educating, and walking alongside the patient for years, sometimes decades. That lesson became my compass. When I received the Dr. Debashish Danda Memorial Medal, my thoughts went back to him — the man whose vision shaped Indian rheumatology. I remember his farewell day, his warmth, his words, the way he introduced us (students) to other outside faculty. It still feels unreal that he’s gone. But his spirit — of excellence, humility, and deep humanism — will always guide us. Today, I stand on the other side of that long road — grateful beyond words. To my teachers — Dr. John Mathew, Dr. Ashish Jacob Mathew Ashish J Mathew , Dr. Ruchika Goel, to my seniors, colleagues, and juniors, especially Dr. Abhilasha Manwatkar Dr Abhilasha Manwatkar (AIIMS Nagpur) and Dr. Chandhu , to my parents, wife , brothers, and family — thank you. Each of you is a thread in this tapestry of my journey. To God — for holding my hand through every storm — my deepest bow of gratitude. As I look ahead, I carry not just a degree, but countless memories — of patients, teachers, and lessons that no book could teach. The same tears that once fell in exhaustion now shimmer as golden light — a reminder that every struggle has meaning when seen from the summit. This is my small story — a story of faith, fight, and fulfilment. A story that began in helplessness — and ended in hope. #Rheumatology #CMCVellore #DMGraduation #DrDebashishDanda #DreamComeTrue #Gratitude #FromHelplessnessToHope #RheumTwitter CMC Vellore Dr Ihab Suliman Dr Celestino Gutiérrez González MD 🇪🇸🍏🇻🇪 @DrAkhilX Durga Prasanna Misra IRA AMAN SHARMA 🇮🇳 Vinod Ravindran
0:22

Two things happened today that made my heart full. First — I officially graduated as a DM in Clinical Immunology and Rheumatology from the prestigious Christian Medical College, Vellore. Second — I received the Dr. Debashish Danda Memorial Best Outgoing Student Medal. Two moments. One dream. A journey that began years ago in quiet classrooms and long, sleepless nights — and ended today in the glow of gratitude. I come from a family with no medical background. From Calicut Medical College, to TD Medical College, and finally to CMC Vellore — the path was long, uncertain, and often lonely. When I first decided to pursue rheumatology, it wasn’t a calculated choice — it was a feeling, a hunch that this was my cup of tea. I walked into this field thinking rheumatology would be more close to medicine — the one I loved and wanted to be with — even though I hadn’t seen many rheumatology patients before. But CMC taught me the truth. Every single day was a whirlwind of patients — in the OPD, in the wards, in casualty. Every disease I had once read about in Harrison’s now stood before me — not as lines in a textbook, but as human stories. I saw suffering and resilience, fear and hope, silence and strength — all living together in the same faces. And when a patient smiled again after months of pain, that smile carried more meaning than any medal or title ever could. Our HOD once told us something I’ll never forget: “In rheumatology, care is like aiming with a bow — the farther you pull back, the farther your arrow of compassion and understanding will go.” He meant that true care is not just about prescribing drugs — it’s about listening, counselling, educating, and walking alongside the patient for years, sometimes decades. That lesson became my compass. When I received the Dr. Debashish Danda Memorial Medal, my thoughts went back to him — the man whose vision shaped Indian rheumatology. I remember his farewell day, his warmth, his words, the way he introduced us (students) to other outside faculty. It still feels unreal that he’s gone. But his spirit — of excellence, humility, and deep humanism — will always guide us. Today, I stand on the other side of that long road — grateful beyond words. To my teachers — Dr. John Mathew, Dr. Ashish Jacob Mathew Ashish J Mathew , Dr. Ruchika Goel, to my seniors, colleagues, and juniors, especially Dr. Abhilasha Manwatkar Dr Abhilasha Manwatkar (AIIMS Nagpur) and Dr. Chandhu , to my parents, wife , brothers, and family — thank you. Each of you is a thread in this tapestry of my journey. To God — for holding my hand through every storm — my deepest bow of gratitude. As I look ahead, I carry not just a degree, but countless memories — of patients, teachers, and lessons that no book could teach. The same tears that once fell in exhaustion now shimmer as golden light — a reminder that every struggle has meaning when seen from the summit. This is my small story — a story of faith, fight, and fulfilment. A story that began in helplessness — and ended in hope. #Rheumatology #CMCVellore #DMGraduation #DrDebashishDanda #DreamComeTrue #Gratitude #FromHelplessnessToHope #RheumTwitter CMC Vellore Dr Ihab Suliman Dr Celestino Gutiérrez González MD 🇪🇸🍏🇻🇪 @DrAkhilX Durga Prasanna Misra IRA AMAN SHARMA 🇮🇳 Vinod Ravindran

ILLIASUL IBAD

27,441 просмотров • 10 месяцев назад

I listened to the President of the United States use the murder of someone who played a significant role in helping him win the White House to anoint Charlie Kirk a political martyr. It was no coincidence that his death was announced not by a doctor at the hospital or a spokesperson of the family or Turning Point USA. If you have seen the footage of the shooting (which I would not advise), you will have seen there is little doubt he died within minutes at the scene. The announcement of his death was a politically choreographed moment in which Trump could simply not pass up the opportunity for him to be centre of attention. It sickens me that this is what America has become. The people deserve better. As I stated in my post following the shooting there is not one single point on which I agreed with Charlie Kirk, but nobody deserves to be murdered for their political beliefs. I found him morally repugnant. A peddler of misogyny, homophobia and an unapologetic racist who spent his time attempting to poison the minds of young people with his white Christian Nationalist views that are antithetical to Christian teachings. Despite my opinion of him, he did not deserve to die for the beliefs he held and I would fight to defend his right to hold them. He has left behind a wife and 2 small children whose last memory of their father should not be a gaping hole in his neck emptying his life in an ocean of blood on the ground. Nobody deserves that. He fervently believed that the numerous gun deaths in America each year were an acceptable price for the preservation of the second amendment and in a twist of irony he became a martyr to that cause NOT the America that Trump is creating and he painted in his disgusting address to the nation. The flag outside the White House flew at half mast not out of respect, but as an act of performative politics. Let’s not forget that a couple of weeks ago, two young children died while they prayed in a Minnesota catholic church. There were no half mast flags to mark their passing because they held no political value. It is likely there will be acts of retribution as we see right wing politicians and talking heads stoking the fires of political violence. I’m sure Trump is already planning to maximise the political value of Kirk’s death with a made for TV funeral event to cement his martyrdom. These are dark times. I will not shed a tear for Charlie Kirk. America will be subjected to slightly less Christian Nationalist propaganda with his passing. I’ll leave you with his own words in the hope that when he met his maker he didn’t have to attempt to debate his way into heaven, because he may find St Peter quoted him Matthew 25:40 ‘I tell you the truth, when you did it to one of the least of these my brothers and sisters, you were doing it to me.
0:33

I listened to the President of the United States use the murder of someone who played a significant role in helping him win the White House to anoint Charlie Kirk a political martyr. It was no coincidence that his death was announced not by a doctor at the hospital or a spokesperson of the family or Turning Point USA. If you have seen the footage of the shooting (which I would not advise), you will have seen there is little doubt he died within minutes at the scene. The announcement of his death was a politically choreographed moment in which Trump could simply not pass up the opportunity for him to be centre of attention. It sickens me that this is what America has become. The people deserve better. As I stated in my post following the shooting there is not one single point on which I agreed with Charlie Kirk, but nobody deserves to be murdered for their political beliefs. I found him morally repugnant. A peddler of misogyny, homophobia and an unapologetic racist who spent his time attempting to poison the minds of young people with his white Christian Nationalist views that are antithetical to Christian teachings. Despite my opinion of him, he did not deserve to die for the beliefs he held and I would fight to defend his right to hold them. He has left behind a wife and 2 small children whose last memory of their father should not be a gaping hole in his neck emptying his life in an ocean of blood on the ground. Nobody deserves that. He fervently believed that the numerous gun deaths in America each year were an acceptable price for the preservation of the second amendment and in a twist of irony he became a martyr to that cause NOT the America that Trump is creating and he painted in his disgusting address to the nation. The flag outside the White House flew at half mast not out of respect, but as an act of performative politics. Let’s not forget that a couple of weeks ago, two young children died while they prayed in a Minnesota catholic church. There were no half mast flags to mark their passing because they held no political value. It is likely there will be acts of retribution as we see right wing politicians and talking heads stoking the fires of political violence. I’m sure Trump is already planning to maximise the political value of Kirk’s death with a made for TV funeral event to cement his martyrdom. These are dark times. I will not shed a tear for Charlie Kirk. America will be subjected to slightly less Christian Nationalist propaganda with his passing. I’ll leave you with his own words in the hope that when he met his maker he didn’t have to attempt to debate his way into heaven, because he may find St Peter quoted him Matthew 25:40 ‘I tell you the truth, when you did it to one of the least of these my brothers and sisters, you were doing it to me.

𝔗𝔯𝔲𝔱𝔥 𝔐𝔞𝔱𝔱𝔢𝔯𝔰

1,224,118 просмотров • 1 год назад